DuPont Co. agreed to pay $44.5 million to settle consumer lawsuits accusing the second-largest U.S. chemical company's drug unit of seeking to monopolize the market for blood-thinning drugs.
A federal judge in Delaware gave preliminary approval to the settlement of five antitrust lawsuits over DuPont's campaign to block approval of a generic version of its blood thinner Coumadin, DuPont officials said.
